A Study of CC-95266 in Participants With Relapsed and/or Refractory Multiple Myeloma
Public ClinicalTrials.gov record NCT04674813. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1, Multicenter, Open-Label Study of CC-95266 in Subjects With Relapsed and/or Refractory Multiple Myeloma
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study is to evaluate the safety and preliminary efficacy of CC-95266 in participants with relapsed and/or refractory multiple myeloma (R/R MM).
Study identification
- NCT ID
- NCT04674813
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1
- Enrollment
- 130 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Feb 23, 2021
- Primary completion
- Dec 21, 2025
- Completion
- Dec 21, 2025
- Last update posted
- Feb 8, 2026
2021 – 2025
United States locations
- U.S. sites
- 10
- U.S. states
- 9
- U.S. cities
- 10
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Local Institution - 005 | Birmingham | Alabama | 10016 | — |
| Local Institution - 009 | Duarte | California | 91010-301 | — |
| Local Institution - 012 | San Francisco | California | 94143 | — |
| Local Institution - 002 | Denver | Colorado | 80218 | — |
| Local Institution - 008 | Baltimore | Maryland | 21201 | — |
| Local Institution - 010 | Boston | Massachusetts | 02215 | — |
| Local Institution - 011 | New York | New York | 10029 | — |
| Local Institution - 001 | Nashville | Tennessee | 37203 | — |
| Local Institution - 006 | Dallas | Texas | 75390 | — |
| Local Institution - 003 | Seattle | Washington | 98104 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04674813, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Feb 8, 2026 · Synced Sep 25, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT04674813 live on ClinicalTrials.gov.